Several foreign drugmakers have announced debuts for their new drugs in the Chinese market since the beginning of 2025, as ...

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria A retrospective study was ...

Erdafitinib received full FDA approval for FGFR3-positive urothelial carcinoma, demonstrating improved overall survival in the phase 3 THOR trial. Cefepime ...

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I drugs for Lung Adenocarcinoma does not have sufficient ...

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. CDER Director ...